Abliva AB (NEVPF)
0.01
0.00 (0.00%)
USD |
OTCM |
May 16, 16:00
Abliva Enterprise Value: 7.716M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 7.716M |
| May 16, 2024 | 7.716M |
| May 15, 2024 | 7.716M |
| May 14, 2024 | 7.716M |
| May 13, 2024 | 7.716M |
| May 10, 2024 | 7.716M |
| May 09, 2024 | 7.716M |
| May 08, 2024 | 7.716M |
| May 07, 2024 | 7.716M |
| May 06, 2024 | 7.716M |
| May 03, 2024 | 7.716M |
| May 02, 2024 | 7.716M |
| May 01, 2024 | 7.716M |
| April 30, 2024 | 7.716M |
| April 29, 2024 | 7.716M |
| April 26, 2024 | 7.716M |
| April 25, 2024 | 7.716M |
| April 24, 2024 | 4.835M |
| April 23, 2024 | 4.835M |
| April 22, 2024 | 4.835M |
| April 19, 2024 | 4.835M |
| April 18, 2024 | 4.835M |
| April 17, 2024 | 4.835M |
| April 16, 2024 | 4.835M |
| April 15, 2024 | 4.835M |
| Date | Value |
|---|---|
| April 12, 2024 | 4.835M |
| April 11, 2024 | 4.835M |
| April 10, 2024 | 4.835M |
| April 09, 2024 | 4.835M |
| April 08, 2024 | 4.835M |
| April 05, 2024 | 4.835M |
| April 04, 2024 | 4.835M |
| April 03, 2024 | 4.835M |
| April 02, 2024 | 4.835M |
| April 01, 2024 | 4.835M |
| March 28, 2024 | 4.835M |
| March 27, 2024 | 4.835M |
| March 26, 2024 | 4.835M |
| March 25, 2024 | 4.835M |
| March 22, 2024 | 4.835M |
| March 21, 2024 | 4.835M |
| March 20, 2024 | 4.835M |
| March 19, 2024 | 4.835M |
| March 18, 2024 | 4.835M |
| March 15, 2024 | 4.835M |
| March 14, 2024 | 4.835M |
| March 13, 2024 | 4.835M |
| March 12, 2024 | 4.835M |
| March 11, 2024 | 4.835M |
| March 08, 2024 | 4.835M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-5.872M
Minimum
Jun 30 2023
54.76M
Maximum
Oct 15 2021
15.76M
Average
18.18M
Median
Jan 20 2022
Enterprise Value Benchmarks
| Karolinska Development AB | 62.17M |
| Calliditas Therapeutics AB | 592.09M |
| Oncopeptides AB | 12.46M |
| Olink Holding AB | 2.869B |
| BioInvent International AB | 209.39M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.377M |
| Revenue (Quarterly) | 0.0129M |
| Total Expenses (Quarterly) | 2.598M |
| EPS Diluted (Quarterly) | -0.0019 |
| Profit Margin (Quarterly) | -18.42K% |
| Earnings Yield | -84.88% |
| Normalized Earnings Yield | -84.91 |